NH SPAC 2 Total Liabilities

Latest as of December 2025: ₩37.46 Billion KRW ≈ $25.38 Million USD

NH SPAC 2 total liabilities. Based on the latest financial reports, NH SPAC 2 (206640) has total liabilities worth ₩37.46 Billion KRW (≈ $25.38 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 206640 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of NH SPAC 2 (2015–2025)

Total liabilities of NH SPAC 2 from 2015 to 2025. This chart illustrates how NH SPAC 2's total liabilities have evolved over time, based on quarterly financial data. Explore 206640 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

NH SPAC 2 Competitors by Total Liabilities

The table below lists competitors of NH SPAC 2 ranked by their total liabilities.

Company Country Total Liabilities
Mostostal Zabrze - Holding SA
WAR:MSZ
Poland zł698.80 Million
John Hancock Income Securities Closed Fund
NYSE:JHS
USA $93.25 Million
GaeaSoft Corp
KQ:051160
Korea ₩90.81 Billion
Southern Hydropower JSC
VN:SHP
Vietnam ₫64.87 Billion
RumbleON Inc
NASDAQ:RMBL
USA $717.00 Million
Teladan Setia Group Bhd
KLSE:0230
Malaysia RM398.22 Million
Cancer Rop Co. Ltd.
KQ:180400
Korea ₩24.60 Billion
JINSUNG T.E.C. Inc
KQ:036890
Korea ₩216.64 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down NH SPAC 2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NH SPAC 2 (206640) total assets.

Liquidity & Leverage Metrics

NH SPAC 2 Total Liabilities Ratios Explained

NH SPAC 2 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 5.24 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.16 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.13 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how NH SPAC 2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for NH SPAC 2 (2015–2025)

The table below shows the annual total liabilities of NH SPAC 2 from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 ₩37.46 Billion
≈ $25.38 Million
+18.45%
2024-12-31 ₩31.62 Billion
≈ $21.43 Million
+3.73%
2023-12-31 ₩30.49 Billion
≈ $20.66 Million
-5.03%
2022-12-31 ₩32.10 Billion
≈ $21.75 Million
-22.00%
2021-12-31 ₩41.15 Billion
≈ $27.89 Million
-5.65%
2020-12-31 ₩43.62 Billion
≈ $29.56 Million
+57.37%
2019-12-31 ₩27.71 Billion
≈ $18.78 Million
-27.28%
2018-12-31 ₩38.11 Billion
≈ $25.83 Million
-5.42%
2017-12-31 ₩40.29 Billion
≈ $27.31 Million
+157.90%
2016-12-31 ₩15.62 Billion
≈ $10.59 Million
+28.06%
2015-12-31 ₩12.20 Billion
≈ $8.27 Million
--

About NH SPAC 2

KQ:206640 Korea Medical Devices
Market Cap
$121.47 Million
₩179.25 Billion KRW
Market Cap Rank
#18264 Global
#802 in Korea
Share Price
₩8360.00
Change (1 day)
-1.76%
52-Week Range
₩8360.00 - ₩13970.00
All Time High
₩36222.75
About

Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testi… Read more